Telix Pharmaceuticals (ASX:TLX) has taken another step in its push to bring novel radiopharmaceutical therapies to men with advanced prostate cancer, confirming that the first patient has now been treated in the randomised expansion phase of its pivotal ProstACT Global Phase 3 trial. …
Telix doses first patient in expanded Phase 3 prostate cancer trial
December 8, 2025 Australian Biotech
Latest Video
New Stories
-
BMS therapy secures Australian approval for psoriatic arthritis
September 3, 2026 - -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - -
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech